Abstract
Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.
| Original language | English |
|---|---|
| Pages (from-to) | 647-662 |
| Number of pages | 16 |
| Journal | Journal of Surgical Oncology |
| Volume | 115 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 May 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adjuvant
- biomarkers
- breast neoplasms
- chemotherapy
- clinical decision-making
- gene expression
- genomics risk
- prognosis
- tumor
Fingerprint
Dive into the research topics of 'Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver